Hugh S Markus Selected Research

Leukoaraiosis

11/2014	Blood-brain barrier dysfunction and cerebral small vessel disease (arteriolosclerosis) in brains of older people.
4/2009	Reduced N-acetylaspartate is consistent with axonal dysfunction in cerebral small vessel disease.
11/2008	Homocysteine and its relationship to stroke subtypes in a UK black population: the south London ethnicity and stroke study.
1/2004	Homocysteine is a risk factor for cerebral small vessel disease, acting via endothelial dysfunction.
8/2003	Frequency of subclinical lacunar infarcts in ischemic leukoaraiosis and cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy.
2/2003	Markers of endothelial dysfunction in lacunar infarction and ischaemic leukoaraiosis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hugh S Markus Research Topics

Disease

84	Stroke (Strokes) 05/2022 - 06/2003
35	Ischemic Stroke 09/2021 - 08/2003
16	Atherosclerosis 10/2018 - 04/2002
15	Carotid Stenosis (Carotid Artery Stenosis) 10/2014 - 03/2002
14	Lacunar Stroke 01/2022 - 02/2003
13	Cerebral Small Vessel Diseases 01/2022 - 01/2004
12	Dementia (Dementias) 01/2022 - 11/2014
11	Inflammation (Inflammations) 01/2022 - 02/2002
10	CADASIL 05/2022 - 08/2003
10	Pathologic Constriction (Stenosis) 01/2022 - 03/2005
10	Cardiovascular Diseases (Cardiovascular Disease) 01/2021 - 04/2002
8	Hypertension (High Blood Pressure) 01/2019 - 11/2007
8	Embolic Stroke 01/2019 - 03/2005
8	Hemorrhage 01/2018 - 08/2010
7	Transient Ischemic Attack 01/2018 - 04/2012
6	Cognitive Dysfunction 01/2022 - 04/2008
6	Disease Progression 02/2021 - 05/2004
6	Alzheimer Disease (Alzheimer's Disease) 09/2020 - 04/2008
6	Coronary Artery Disease (Coronary Atherosclerosis) 01/2020 - 05/2004
6	Leukoaraiosis 11/2014 - 02/2003
6	Carotid Artery Diseases 06/2011 - 02/2003
5	Atrial Fibrillation 01/2020 - 06/2002
5	Myocardial Infarction 07/2014 - 12/2006
4	Genetic Predisposition to Disease (Genetic Predisposition) 01/2021 - 02/2016
4	Cerebral Amyloid Angiopathy (Congophilic Angiopathy) 01/2021 - 11/2014
3	Atrophy 01/2022 - 01/2011
3	Cerebrovascular Disorders (Cerebrovascular Occlusion) 01/2021 - 05/2014
3	Insulin Resistance 01/2021 - 05/2004
3	Thrombosis (Thrombus) 01/2020 - 12/2008
3	Vascular Diseases (Vascular Disease) 10/2018 - 06/2009
3	Genetic Risk Score 10/2017 - 01/2016
3	Intracranial Embolism 03/2015 - 02/2007
2	COVID-19 10/2021 - 01/2020
2	Brain Ischemia (Cerebral Ischemia) 09/2021 - 03/2015
2	Vascular Dementia (Subcortical Arteriosclerotic Encephalopathy) 01/2021 - 04/2008
2	Neuroinflammatory Diseases 09/2020 - 11/2017
2	Blood Vessel Dissection 01/2019 - 02/2017
2	Type 2 Diabetes Mellitus (MODY) 08/2017 - 02/2011
2	Schizophrenia (Dementia Praecox) 01/2017 - 01/2016
2	Atherosclerotic Plaque (Atheroma) 01/2017 - 05/2013
2	Infections 02/2016 - 02/2002
2	Vertebral Artery Dissection 04/2015 - 08/2012
2	Acute Coronary Syndrome 10/2013 - 04/2012
2	Venous Thromboembolism 09/2013 - 08/2012

Drug/Important Bio-Agent (IBA)

22	Biomarkers (Surrogate Marker)IBA 01/2022 - 08/2003
9	AnticoagulantsIBA 09/2021 - 06/2002
9	danaparoid (Orgaran)FDA Link 01/2019 - 06/2003
8	C-Reactive ProteinIBA 01/2022 - 04/2002
8	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 01/2017 - 03/2002
7	Fibrinogen (Factor I)FDA Link 01/2022 - 09/2013
7	HomocysteineIBA 01/2019 - 01/2004
7	Clopidogrel (Plavix)FDA Link 01/2017 - 05/2005
6	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 01/2015
6	Platelet Aggregation Inhibitors (Antiplatelet Drugs)IBA 01/2019 - 03/2005
5	Glucose (Dextrose)FDA LinkGeneric 01/2022 - 09/2006
4	Proteins (Proteins, Gene)FDA Link 05/2022 - 04/2008
4	LipidsIBA 01/2022 - 01/2018
4	Amyloid (Amyloid Fibrils)IBA 01/2021 - 11/2017
4	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2018 - 11/2014
3	Cysteine (L-Cysteine)FDA Link 05/2022 - 01/2019
3	Histone Deacetylase InhibitorsIBA 01/2022 - 07/2014
3	CreatinineIBA 01/2022 - 12/2014
3	Histone Deacetylases (Histone Deacetylase)IBA 01/2022 - 02/2012
3	Tissue Plasminogen Activator (Alteplase)FDA Link 09/2021 - 02/2006
3	Apolipoproteins E (ApoE)IBA 01/2021 - 09/2004
3	MicroRNAs (MicroRNA)IBA 01/2021 - 02/2013
3	Folic Acid (Vitamin M)FDA LinkGeneric 01/2019 - 11/2008
3	Vitamin B 12 (Cyanocobalamin)FDA LinkGeneric 01/2019 - 11/2008
2	Notch3 ReceptorIBA 05/2022 - 01/2019
2	Epidermal Growth Factor (EGF)IBA 05/2022 - 01/2019
2	Lipoproteins (Lipoprotein)IBA 01/2022 - 01/2017
2	Pharmaceutical PreparationsIBA 01/2021 - 01/2018
2	Hypoglycemic Agents (Hypoglycemics)IBA 01/2021 - 01/2018
2	Interleukin-6 (Interleukin 6)IBA 01/2019 - 02/2003
2	Nitric Oxide (Nitrogen Monoxide)FDA Link 12/2018 - 03/2016
2	P-2 (P 2)IBA 12/2018 - 12/2012
2	VitaminsIBA 10/2018 - 01/2018
2	25-hydroxyvitamin DIBA 10/2018 - 09/2018
2	Antihypertensive Agents (Antihypertensives)IBA 01/2018 - 08/2010
2	Anticonvulsants (Antiepileptic Drugs)IBA 01/2018 - 07/2014
2	LDL CholesterolIBA 01/2018 - 05/2014
2	Insulin (Novolin)FDA Link 01/2018 - 08/2017
2	Valproic Acid (Depakote)FDA LinkGeneric 01/2018 - 07/2014
2	Dipyridamole (Persantine)FDA LinkGeneric 01/2017 - 10/2015
2	Peptide Hydrolases (Proteases)FDA Link 01/2017 - 12/2008
2	Oxygen (Dioxygen)IBA 02/2016 - 03/2015
2	Blood Proteins (Serum Proteins)IBA 01/2016 - 11/2014
2	Collagen Type IV (Type IV Collagen)IBA 12/2015 - 08/2010
2	Blood Coagulation Factors (Coagulation Factor)IBA 08/2015 - 01/2013
2	Immunoglobulin G (IgG)IBA 11/2014 - 08/2003
2	Messenger RNA (mRNA)IBA 07/2014 - 05/2013
2	AdipokinesIBA 09/2013 - 06/2011

Therapy/Procedure

40	Therapeutics 01/2022 - 03/2002
8	Secondary Prevention 01/2022 - 05/2010
8	Carotid Endarterectomy 04/2014 - 10/2002
6	Thrombectomy 01/2022 - 01/2020
4	Endarterectomy (Thromboendarterectomy) 04/2014 - 10/2009
3	Stents 08/2019 - 09/2017
2	Activities of Daily Living (ADL) 10/2016 - 05/2016
2	Aftercare (After-Treatment) 04/2014 - 10/2009